Preclinical, in vitro/murine; clinically advanced miRNA mimic relevant to oncology—TargomiRs/mesomiR-16 (miR-16 mimic in EGFR-targeted minicells, EnGeneIC) completed Phase I in malignant pleural mesothelioma and NSCLC (NCT02369198, 2014–2017) with acceptable safety and disease stabilization signals, but no further development or MM trial as of 2025. This evidence concerns the gene EGFR and Miyoshi myopathy.